With its ex-No­var­tis can­cer drug near the fin­ish line, Ad­lai Nortye rais­es $97.5M in Nas­daq de­but

The Nas­daq is wel­com­ing an­oth­er com­pa­ny hus­tling along a late-stage drug, with Ad­lai Nortye rais­ing $97.5 mil­lion from an IPO and a con­cur­rent pri­vate place­ment.

Ad­lai Nortye li­censed its lead pro­gram, the PI3K in­hibitor bu­parlis­ib, from No­var­tis back in 2018 and has since steered it in­to a Phase III tri­al for squa­mous cell car­ci­no­ma of the head and neck. Its sec­ond drug, now in Phase Ib, was li­censed from Ei­sai, and the pipeline fea­tures one more clin­i­cal pro­gram and three pre­clin­i­cal ones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER